Debt-to-equity improved to 0.59 from 0.82 over the past year as total debt fell to $1.3B, though goodwill of $1.5B represents 37.5% of total assets and warrants monitoring for impairment.
ICU Medical, Inc. (ICUI) balance sheet — 30-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Total Current Assets | 1.22B | 1.18B | 1.44B | 1.22B | 1.24B | 1.03B | 914.38M | 882.2M | 927.04M | 864.66M | 569.1M | 505.01M | 437.21M | 394.3M | 325.5M | 262.99M | 207.83M | 207.94M | 179.39M | 153.26M | 171.44M | 137.76M | 117.04M | 111.22M | 114.21M | 90.4M | 67.2M | 49.4M | 47.9M | 41.1M | 38.2M |
| Cash & Short-Term Investments | 301.78M | 307.96M | 308.57M | 254.72M | 213.01M | 567.25M | 410.78M | 292.64M | 382.11M | 300.13M | 445.08M | 377.4M | 346.76M | 296.89M | 226.16M | 159.99M | 93.36M | 108.14M | 111.79M | 95.64M | 116.92M | 86.74M | 87.34M | 73.14M | 88.47M | 73.03M | 50.79M | 38.4M | 2M | 3M | 2.1M |
| Cash Only | 301.78M | 307.96M | 308.57M | 254.22M | 208.78M | 552.83M | 396.1M | 268.67M | 344.78M | 290.07M | 445.08M | 336.16M | 275.81M | 226.02M | 146.9M | 99.59M | 78.85M | 51.25M | 55.7M | 7.87M | 13.15M | 6.85M | 5.62M | 1.79M | 4.17M | 3.9M | 1.95M | 1.9M | 2M | 3M | 2.1M |
| Short-Term Investments | 0 | 0 | 0 | 501K | 4.22M | 14.42M | 14.69M | 23.97M | 37.33M | 10.06M | 0 | 41.23M | 70.95M | 70.87M | 79.26M | 60.4M | 14.51M | 56.89M | 56.09M | 87.77M | 103.77M | 79.89M | 81.72M | 71.35M | 84.3M | 69.13M | 48.84M | 36.5M | 0 | 0 | 0 |
| Accounts Receivable | 206.26M | 180.51M | 202.7M | 182.15M | 246.9M | 124.81M | 127.77M | 202.22M | 196.44M | 149.12M | 59.11M | 57.85M | 39.05M | 45.32M | 49.13M | 43.57M | 55.11M | 47.78M | 38.42M | 26.11M | 26.61M | 24.82M | 11.56M | 29.09M | 16.63M | 13.06M | 12.43M | 7.1M | 6.5M | 3.4M | 3M |
| Days Sales Outstanding | 33.71 | 29.55 | 31.06 | 29.43 | 39.53 | 34.61 | 36.69 | 58.29 | 51.21 | 42.11 | 56.87 | 61.8 | 46.09 | 52.73 | 56.59 | 52.63 | 70.68 | 75.32 | 68.5 | 50.66 | 48.17 | 57.51 | 55.83 | 98.89 | 69.14 | 69.04 | 80.71 | 55.14 | 59.61 | 40.82 | 44.51 |
| Inventory | 607.27M | 615.86M | 584.68M | 709.36M | 696.01M | 290.24M | 314.93M | 337.64M | 311.16M | 288.66M | 49.26M | 43.63M | 36.93M | 34.45M | 36.33M | 40.42M | 44.06M | 41.33M | 17.93M | 19.5M | 16.32M | 15.44M | 8.43M | 3.4M | 5.75M | 1.59M | 1.44M | 2.1M | 2M | 1.8M | 2.2M |
| Days Inventory Outstanding | 166.17 | 159.38 | 137.04 | 170.42 | 160.56 | 128.44 | 142 | 155.15 | 136.83 | 121.59 | 101.03 | 99 | 85.4 | 79.09 | 82.7 | 92.31 | 104.43 | 122.94 | 56.95 | 64.78 | 49.24 | 63.93 | 77.2 | 25.6 | 57.55 | 20.11 | 27.32 | 47.91 | 51.05 | 61.4 | 95.6 |
| Other Current Assets | 104.56M | 47.63M | 321.42M | 41.01M | 43.05M | 20.27M | 25.24M | 27.16M | 21.1M | 38.89M | 13.99M | 18.5M | 10.5M | 10.32M | 11.56M | 10.84M | 14.63M | 8.71M | 6.7M | 9.26M | 7.06M | 7M | 3.14M | 2.01M | 1.71M | 2.11M | 2.55M | 1.8M | 37.4M | 32.9M | 30.9M |
| Total Non-Current Assets | 2.72B | 2.86B | 2.76B | 3.16B | 3.28B | 850.93M | 849.32M | 810.18M | 658.36M | 632.29M | 135.59M | 121.82M | 103.89M | 105.35M | 103.01M | 100.7M | 104.39M | 101.22M | 104.05M | 89.34M | 72.81M | 66.78M | 47.72M | 53.07M | 42.82M | 26.94M | 25.66M | 26M | 14.5M | 10.1M | 11.4M |
| Property, Plant & Equipment | 481.16M | 506.29M | 499.3M | 685.52M | 713.58M | 510.88M | 513.2M | 490.55M | 432.64M | 398.68M | 85.7M | 74.32M | 86.09M | 87.86M | 85.94M | 83.05M | 83.55M | 78.39M | 69.9M | 72.71M | 59.04M | 52.19M | 40.93M | 41.04M | 34.61M | 25.12M | 23.92M | 24.4M | 13.8M | 9.6M | 10.9M |
| Fixed Asset Turnover | 4.42x | 4.40x | 4.77x | 3.30x | 3.20x | 2.58x | 2.48x | 2.58x | 3.24x | 3.24x | 4.43x | 4.60x | 3.59x | 3.57x | 3.69x | 3.64x | 3.41x | 2.95x | 2.93x | 2.59x | 3.42x | 3.02x | 1.85x | 2.62x | 2.54x | 2.75x | 2.35x | 1.93x | 2.88x | 3.17x | 2.26x |
| Goodwill | 1.48B | 1.5B | 1.43B | 1.47B | 1.45B | 43.44M | 33M | 31.25M | 11.2M | 12.36M | 5.58M | 6.46M | 1.48M | 1.48M | 1.48M | 1.48M | 1.48M | 1.48M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 536.47M | 633.56M | 740.79M | 870.59M | 982.77M | 188.31M | 197.23M | 211.41M | 133.42M | 143.75M | 22.38M | 23.94M | 7.06M | 8.49M | 9.95M | 11.42M | 14.81M | 16.78M | 10.78M | 11.88M | 9.78M | 10.96M | 2.78M | 4.17M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 526.1M | 131.59M | 8.76M | 3.12M | 3.69M | 7.86M | 12.97M | 0 | 2.02M | 14.58M | -21.93M | -17.1M | -13.94M | -7.52M | 97.37M | 0 | 0 | -3.71M | 11.35M | 0 | 0 | 0 | -1.16M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 69.16M | 62.88M | 56.11M | 88.19M | 99.69M | 57.83M | 61.88M | 48.98M | 40.42M | 38.14M | 21.93M | 17.1M | 13.94M | 7.52M | -97.37M | 0 | 0 | 4.57M | 8.16M | 2.31M | 1.11M | 2.9M | 4.01M | 5.18M | 3.9M | 856K | 1.74M | 1.6M | 700K | 500K | 500K |
| Total Assets | 3.94B | 4.05B | 4.2B | 4.38B | 4.52B | 1.88B | 1.76B | 1.69B | 1.59B | 1.5B | 704.69M | 626.83M | 541.1M | 499.64M | 428.51M | 363.69M | 312.23M | 309.15M | 283.43M | 242.59M | 244.25M | 204.54M | 164.77M | 164.29M | 157.03M | 117.34M | 92.86M | 75.4M | 62.4M | 51.2M | 49.6M |
| Asset Turnover | 0.55x | 0.55x | 0.57x | 0.52x | 0.50x | 0.70x | 0.72x | 0.75x | 0.88x | 0.86x | 0.54x | 0.55x | 0.57x | 0.63x | 0.74x | 0.83x | 0.91x | 0.75x | 0.72x | 0.78x | 0.83x | 0.77x | 0.46x | 0.65x | 0.56x | 0.59x | 0.61x | 0.62x | 0.64x | 0.59x | 0.50x |
| Asset Growth % | -14.92% | -3.65% | -3.99% | -3.04% | 140.1% | 6.64% | 4.21% | 6.75% | 5.91% | 112.43% | 12.42% | 15.84% | 8.3% | 16.6% | 17.82% | 16.48% | 0.99% | 9.07% | 16.83% | -0.68% | 19.42% | 24.14% | 0.29% | 4.62% | 33.82% | 26.36% | 23.16% | 20.83% | 21.88% | 3.23% | 3.55% |
| Total Current Liabilities | 514.63M | 498.86M | 556.18M | 481.84M | 494.56M | 200.78M | 195.49M | 248.47M | 249.29M | 210.29M | 40.54M | 42.62M | 28.73M | 26.89M | 29.12M | 29.31M | 25.76M | 33.7M | 21.96M | 21.48M | 15.92M | 13.89M | 7.45M | 8.29M | 11.64M | 10.66M | 9.48M | 7.4M | 4.1M | 3.2M | 2.7M |
| Accounts Payable | 142.99M | 154.37M | 148.02M | 150.03M | 215.9M | 81.13M | 71.86M | 128.63M | 120.47M | 78.23M | 14.64M | 13.67M | 11.38M | 11.34M | 11.31M | 13.25M | 10.88M | 18.42M | 7.88M | 8.44M | 8.13M | 5.08M | 2.69M | 3.05M | 5.05M | 2.4M | 1.69M | 1M | 700K | 1.4M | 1.9M |
| Days Payables Outstanding | 42.33 | 39.95 | 34.69 | 36.04 | 49.81 | 35.9 | 32.4 | 59.1 | 52.98 | 32.95 | 30.03 | 31.02 | 26.31 | 26.02 | 25.74 | 30.26 | 25.79 | 54.81 | 25.03 | 28.03 | 24.54 | 21.03 | 24.66 | 22.99 | 50.51 | 30.29 | 32.11 | 22.81 | 17.87 | 47.76 | 82.56 |
| Short-Term Debt | 18.75M | 34.67M | 51M | 51M | 29.69M | 0 | 9.29M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 212.24M | 33.84M | 30.36M | 31.64M | 30.84M | 12.65M | 5.57M | 6.7M | 3.81M | 3.33M | 0 | 0 | 0 | 0 | 0 | 0 | 254K | 2.39M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 10.09M | 134.25M | 103.17M | 71.21M | 42.93M | 33.11M | 53.51M | 15.22M | 58.61M | 67.31M | 12.28M | 8.14M | 1.37M | 0 | 5.16M | 3.68M | 5.61M | 5.34M | 0 | 7.67M | 2.38M | 4.22M | 2.31M | 0 | 0 | 0 | 7.79M | 6.4M | 3.4M | 1.8M | 800K |
| Current Ratio | 2.37x | 2.36x | 2.59x | 2.53x | 2.50x | 5.13x | 4.68x | 3.55x | 3.72x | 4.11x | 14.04x | 11.85x | 15.22x | 14.67x | 11.18x | 8.97x | 8.07x | 6.17x | 8.17x | 7.14x | 10.77x | 9.92x | 15.70x | 13.42x | 9.81x | 8.48x | 7.09x | 6.68x | 11.68x | 12.84x | 14.15x |
| Quick Ratio | 1.19x | 1.13x | 1.54x | 1.06x | 1.09x | 3.68x | 3.07x | 2.19x | 2.47x | 2.74x | 12.82x | 10.83x | 13.93x | 13.38x | 9.93x | 7.59x | 6.36x | 4.94x | 7.35x | 6.23x | 9.74x | 8.81x | 14.57x | 13.01x | 9.31x | 8.33x | 6.94x | 6.39x | 11.20x | 12.28x | 13.33x |
| Cash Conversion Cycle | 157.56 | 148.98 | 133.4 | 163.81 | 150.28 | 127.14 | 146.29 | 154.33 | 135.07 | 130.75 | 127.88 | 129.78 | 105.18 | 105.8 | 113.55 | 114.67 | 149.32 | 143.46 | 100.43 | 87.42 | 72.87 | 100.41 | 108.36 | 101.5 | 76.18 | 58.86 | 75.91 | 80.23 | 92.79 | 54.47 | 57.55 |
| Total Non-Current Liabilities | 1.24B | 1.43B | 1.68B | 1.77B | 1.93B | 63.93M | 65.94M | 66.67M | 72.45M | 88.41M | 4M | 4.34M | 4.12M | 8.03M | 8.54M | 11.22M | 12.18M | 10.45M | 8.44M | 7.21M | 3.08M | 529K | 0 | 0 | 0 | 0 | 0 | 0 | 100K | 100K | 200K |
| Long-Term Debt | 1.13B | 1.31B | 1.53B | 1.58B | 1.62B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 133.28M | 47.68M | 43.11M | 54.93M | 62.77M | 36.04M | 43.41M | 28.9M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 73.26M | 37.76M | 48.81M | 55.87M | 126.01M | 1.49M | 1.66M | 2.09M | 721K | 1.49M | 1.37M | 1.37M | 1.38M | 3.63M | 5.25M | 7.14M | 8.02M | 5.7M | 8.44M | 4.33M | 3.08M | 529K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100K | 200K |
| Other Non-Current Liabilities | 95.89M | 32.52M | 49.69M | 74.04M | 102.46M | 26.4M | 19.67M | 35.12M | 71.73M | 86.92M | 2.63M | 2.96M | 2.75M | 4.4M | 3.29M | 4.08M | 4.16M | 4.75M | 0 | 2.89M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100K | 0 | 0 |
| Total Liabilities | 1.75B | 1.93B | 2.24B | 2.26B | 2.43B | 264.71M | 261.43M | 315.14M | 321.74M | 298.7M | 44.53M | 46.95M | 32.85M | 34.92M | 37.66M | 40.53M | 37.94M | 44.15M | 30.4M | 28.69M | 19M | 14.42M | 7.45M | 8.29M | 11.64M | 10.66M | 9.48M | 7.4M | 4.2M | 3.3M | 2.9M |
| Total Debt | 1.15B | 1.39B | 1.64B | 1.7B | 1.73B | 45.05M | 52.7M | 36.26M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | 850.07M | 1.08B | 1.33B | 1.45B | 1.53B | -507.78M | -343.4M | -232.41M | -344.78M | -290.07M | -445.08M | -336.16M | -275.81M | -226.02M | -146.9M | -99.59M | -78.85M | -51.25M | -55.7M | -7.87M | -13.15M | -6.85M | -5.62M | -1.79M | -4.17M | -3.9M | -1.95M | -1.9M | -2M | -3M | -2.1M |
| Debt / Equity | 0.53x | 0.66x | 0.84x | 0.80x | 0.83x | 0.03x | 0.04x | 0.03x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | 3.28x | 4.52x | 6.25x | 6.77x | 9.02x | 0.21x | 0.27x | 0.20x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 2.42x | 3.52x | 5.08x | 5.76x | 7.93x | -2.38x | -1.78x | -1.26x | -3.58x | -5.63x | -4.36x | -3.88x | -4.72x | -3.16x | -1.83x | -1.19x | -1.18x | -0.96x | -1.22x | -0.22x | -0.31x | -0.18x | -0.39x | -0.04x | -0.12x | -0.14x | -0.09x | -0.11x | -0.16x | -0.30x | -0.26x |
| Interest Coverage | 1.00x | 1.03x | 0.38x | 0.24x | -0.62x | 144.72x | 56.62x | 209.94x | 278.08x | 26.05x | 722.73x | 1788.15x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 2.19B | 2.12B | 1.97B | 2.12B | 2.09B | 1.62B | 1.5B | 1.38B | 1.26B | 1.2B | 660.15M | 579.87M | 508.25M | 464.73M | 390.86M | 323.16M | 274.29M | 265M | 253.03M | 213.9M | 225.25M | 190.12M | 157.31M | 156M | 145.39M | 106.68M | 83.38M | 68M | 58.2M | 47.9M | 46.7M |
| Equity Growth % | 19.04% | 8.07% | -7.45% | 1.6% | 29.32% | 7.57% | 9.08% | 8.99% | 5.46% | 81.51% | 13.85% | 14.09% | 9.37% | 18.9% | 20.95% | 17.82% | 3.5% | 4.73% | 18.29% | -5.04% | 18.47% | 20.85% | 0.84% | 7.3% | 36.29% | 27.94% | 22.62% | 16.84% | 21.5% | 2.57% | 2.19% |
| Book Value per Share | 87.15 | 85.28 | 80.58 | 88.14 | 87.56 | 74.19 | 69.58 | 63.92 | 58.50 | 57.45 | 38.26 | 35.15 | 32.48 | 30.43 | 26.54 | 22.82 | 19.80 | 17.69 | 17.37 | 14.01 | 14.44 | 12.64 | 10.52 | 10.37 | 9.47 | 7.38 | 6.14 | 5.22 | 4.61 | 3.98 | 3.52 |
| Total Shareholders' Equity | 2.19B | 2.12B | 1.97B | 2.12B | 2.09B | 1.62B | 1.5B | 1.38B | 1.26B | 1.2B | 660.15M | 579.87M | 508.25M | 464.73M | 390.86M | 323.16M | 274.29M | 265M | 253.03M | 213.9M | 224.89M | 189.2M | 156.35M | 156M | 145.39M | 106.68M | 83.38M | 68M | 58.2M | 47.9M | 46.7M |
| Common Stock | 2.52M | 2.47M | 2.45M | 2.41M | 2.4M | 2.13M | 2.11M | 2.07M | 2.05M | 2.02M | 1.63M | 1.61M | 1.56M | 1.51M | 1.49M | 1.49M | 1.49M | 1.48M | 1.48M | 1.48M | 1.48M | 1.42M | 1.42M | 1.42M | 1.41M | 887K | 887K | 900K | 0 | 0 | 0 |
| Retained Earnings | 766.96M | 690.89M | 690.16M | 807.85M | 837.5M | 911.79M | 808.65M | 721.78M | 620.75M | 585.62M | 516.98M | 453.9M | 408.91M | 382.58M | 342.16M | 303.46M | 258.79M | 227.86M | 201.3M | 177M | 153.93M | 128.26M | 107.99M | 102.99M | 80.69M | 61.01M | 45.61M | 33.4M | 24.2M | 16.9M | 11.3M |
| Treasury Stock | -23.04M | -22K | -92K | -262K | -243K | -27K | -39K | -157K | -95K | 0 | -14K | 0 | 0 | -49K | -15.13M | -35.35M | -41.43M | -19.88M | -1.62M | -40.78M | -5.38M | -609K | -15.29M | -12.12M | 0 | -987K | -4.82M | -7.2M | 0 | 0 | 0 |
| Accumulated OCI | -42.17M | -34.63M | -139.4M | -53.08M | -80.98M | -19.27M | -1.52M | -15.4M | -16.95M | -14.96M | -21.27M | -20.76M | -9.55M | 2.19M | -1.43M | -3.23M | -1.06M | 1.19M | 902K | 1.4M | 381K | -28K | 480K | 177K | -24.35M | -19.82M | -16.21M | -12.5M | -9.1M | -7.1M | -5.2M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 358K | 923K | 966K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying ICUI stock.
As of 2025, ICU Medical, Inc. (ICUI) had total assets of $4.05B including $1.18B in current assets.
ICU Medical, Inc. (ICUI) carries total debt of $1.39B, offset by $308.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
ICU Medical, Inc. (ICUI) has total shareholders' equity (book value) of $2.12B ($85.28 book value per share). Book value represents the net worth of the company belonging to common stock holders.
ICU Medical, Inc. (ICUI) reported a current ratio of 2.36x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Revenue contraction persists
Metrics are mathematically derived from official filings.
Leverage Easing as Assets Shrink
Total assets contracted from $4.3B to $4.0B over the past year while debt fell from $1.7B to $1.3B, per recent balance sheet data, suggesting deleveraging despite revenue decline.
The balance sheet is gradually strengthening as total liabilities dropped from $2.2B to $1.8B over the last five quarters, while equity rose from $2.0B to $2.2B. This deleveraging appears driven by debt repayment and retained earnings accumulation, even as revenue contracts. The asset reduction may reflect divestitures or write-downs, but the improving equity cushion suggests a stabilizing financial base.
Debt Reduction Improves Leverage Profile
Debt-to-equity improved from 0.82 in early 2024 to 0.59 by Q2 2026, as total debt fell from $1.7B to $1.3B, according to reported figures, indicating a deliberate deleveraging trend.
The absolute debt reduction of roughly $400M over ten quarters appears strategic, likely aimed at reducing interest burden post-Smiths Medical acquisition. The D/E ratio now sits below peers like BDX (0.76) and ITGR (0.80), suggesting improved financial flexibility. However, the absolute debt level remains substantial relative to equity, and refinancing risk may persist if rates stay elevated, though the trend is favorable.
Asset Base Shrinks with Goodwill Dominance
Goodwill remains flat at $1.5B, representing 37.5% of total assets, while net PPE declined from $670M to $485M over ten quarters, per balance sheet data, indicating a shift toward intangible-heavy assets.
The high goodwill concentration, largely from the Smiths Medical acquisition, exposes the balance sheet to potential impairment if revenue contraction persists. The decline in net PPE suggests either reduced capital expenditure or asset disposals, which may signal a more asset-light model but could also reflect underinvestment in manufacturing capacity. Investors should monitor whether the shrinking asset base aligns with revenue stabilization.
Equity Builds on Retained Earnings
Retained earnings rose from $768M in Q1 2024 to $740M in Q2 2026, despite a dip to $675M in Q1 2025, as per financial statements, indicating a gradual accumulation of profits.
The equity base expanded from $2.0B to $2.2B over the period, driven by retained earnings and reduced debt, even as net income remained volatile. The absence of dividends and modest buybacks suggests management is prioritizing balance sheet repair over shareholder returns. The positive retained earnings trajectory, despite revenue decline, implies that margin improvements are translating into equity growth.
Liquidity Buffer Remains Solid
Current ratio improved to 2.43 in Q2 2026 from 2.29 in Q3 2024, with cash stable around $300M, according to balance sheet data, indicating a robust short-term liquidity position.
The current ratio consistently above 2.0 suggests ample coverage of short-term obligations, with cash levels sufficient to cover roughly 10% of total liabilities. This liquidity buffer provides a cushion against operational shocks, such as supply chain disruptions or integration delays. However, the stable cash balance despite debt repayment may indicate that operating cash flow is being used to service debt rather than build reserves.
Goodwill Impairment Risk Looms
Goodwill of $1.5B, unchanged over ten quarters, represents a significant 37.5% of total assets, per balance sheet data, and may be at risk if revenue decline continues.
The persistent revenue contraction of 6.4% YoY raises the risk that the carrying value of goodwill from the Smiths Medical acquisition may not be fully recoverable. If the company's market capitalization or cash flow projections deteriorate, an impairment charge could erode equity and distort the apparent balance sheet strength. Investors should monitor whether the recent margin improvements are sufficient to offset top-line weakness and support the goodwill valuation.